To identify factors predictive of post-management secondary glaucoma in eyes with iris melanoma.
Patients with iris melanoma who were conservatively managed on the Ocular Oncology Service, Wills Eye Hospital from 1970 to 2016 were included. Charts were retrospectively reviewed, and binary logistic regression analysis was performed. Main outcome measures were factors predictive of post-management glaucoma, defined as intraocular pressure (IOP) > 22 mmHg following melanoma treatment.
Of 271 patients with iris melanoma, melanoma-related glaucoma was identified in 40 (15%) at presentation and post-management glaucoma developed in 75 (28%) at a mean of 103.7 months (range:1.0-120.0). Comparison (post-management glaucoma vs. no glaucoma) revealed patients with post-management glaucoma presented with worse visual acuity (20/50-20/150) (17% vs. 5%, p = 0.001), increased mean tumour basal diameter (5.1 mm vs. 4.3 mm, p = 0.004), greater melanoma-related increased IOP on presentation (24.1 mmHg vs. 16.2 mmHg, p < 0.001), diffuse tumour shape (9% vs. 4%, p = 0.01), American Joint Committee on Cancer (AJCC) T4 category (7% vs. 2%, p = 0.03), and extraocular tumour extension (7% vs. 2%, p = 0.03). Risk factors for post-management glaucoma identified by multivariate analysis included melanoma-related increased IOP at presentation (OR:1.1, [1.08–1.22] per 1-mmHg increase, p < 0.001), increased mean tumour basal diameter (OR:1.17, [1.02–1.33] per 1-millimetre increments, p = 0.03), advanced AJCC clinical T subcategory (OR:1.23, [1.04–1.46] per 1-subcategory increments, p = 0.02) and plaque radiotherapy treatment (OR:2.32, [1.13–4.75], p = 0.02).
Features of iris melanoma that predicted post-management glaucoma included melanoma-related increased IOP on presentation, advanced AJCC clinical T subcategory, increased mean tumour basal diameter, and plaque radiotherapy treatment.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118:1881–5. https://doi.org/10.1016/j.ophtha.2011.01.040.
Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98. https://doi.org/10.1001/archophthalmol.2009.208.
Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363–72. https://doi.org/10.1097/IAE.0b013e31824d09a8.
Shields CL, Shields JA, De Potter P, Singh AD, Hernandez C, Brady LW. Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy. Br J Ophthalmol. 1995;79:306–12. https://doi.org/10.1136/bjo.79.4.306.
Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: features and prognosis in 317 children and adults. J AAPOS. 2012;16:10–6. https://doi.org/10.1016/j.jaapos.2011.10.012.
Shields CL, Shah SU, Bianciotto CG, Emrich J, Komarnicky L, Shields JA. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes. Ophthalmology 2013;120:55–61. https://doi.org/10.1016/j.ophtha.2012.06.053.
Shields CL, Shields JA, Shields MB, Augsburger JJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology 1987;94:839–46. https://doi.org/10.1016/s0161-6420(87)33537-7.
Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001;108:172–8. https://doi.org/10.1016/s0161-6420(00)00449-8.
Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012;130:57–64. https://doi.org/10.1001/archophthalmol.2011.286.
Fernandes BF, Krema H, Fulda E, Pavlin CJ, Payne DG, McGowan HD, et al. Management of iris melanomas with 125Iodine plaque radiotherapy. Am J Ophthalmol. 2010;149:70–6. https://doi.org/10.1016/j.ajo.2009.08.007.
Shields CL, Materin MA, Shields JA, Gershenbaum E, Singh AD, Smith A. Factors associated with elevated intraocular pressure in eyes with iris melanoma. Br J Ophthalmol. 2001;85:666–9. https://doi.org/10.1136/bjo.85.6.666.
Shields CL, Di Nicola M, Bekerman VP, Kaliki S, Alarcon C, Fulco E, et al. Iris melanoma outcomes based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients. Ophthalmology 2018;125:913–23. https://doi.org/10.1016/j.ophtha.2017.11.040.
Kivelä T, Simpson ER, Grossniklaus HE, et al. Uveal mekanoma. In: AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. p. 805e817.
Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, et al. Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide. Ophthalmology 2013;120:766–72. https://doi.org/10.1016/j.ophtha.2012.09.042.
Bechrakis NE, Bornfeld N, Zoller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 2002;109:1855–61. https://doi.org/10.1016/s0161-6420(02)01273-3.
Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102–10. https://doi.org/10.1093/oxfordjournals.aje.a116013.
Kim EA, Salazar D, McCannel CA, Kamrava M, Demanes DJ, Lamb J, et al. Glaucoma after Iodine-125 Brachytherapy for Uveal melanoma: incidence and risk factors. J Glaucoma 2020;29:1–10. https://doi.org/10.1097/IJG.0000000000001393.
Puusaari I, Heikkonen J, Kivela T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 2004;111:1768–77. https://doi.org/10.1016/j.ophtha.2004.03.027.
Karimi S, Arabi A, Shahraki T. Plaque brachytherapy in iris and iridociliary melanoma: a systematic review of efficacy and complications. J Contemp Brachytherapy. 2021;13:46–50. https://doi.org/10.5114/jcb.2021.103586.
Kaliki S, Eagle RC, Grossniklaus HE, Campbell RJ, Shields CL, Shields JA. Inadvertent implantation of aqueous tube shunts in glaucomatous eyes with unrecognized intraocular neoplasms: report of 5 cases. JAMA Ophthalmol. 2013;131:925–8. https://doi.org/10.1001/jamaophthalmol.2013.828.
Accepted for paper presentation at the Annual Meeting of the American Academy of Ophthalmology from November 13–15, 2020.
Eye Tumor Research Foundation, Philadelphia, PA (CLS) and the American Glaucoma Society’s Mentoring for the Advancement of Physician Scientists Grant (AGS). The funders had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review or approval of the manuscript. No conflicting relationship exists for any author. Aakriti G. Shukla, M.D. has had full access to all the data in the study and takes responsibility for the integrity of the data.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Shukla, A.G., Vaidya, S., Yaghy, A. et al. Iris melanoma: factors predictive of post-management secondary glaucoma in 271 cases at a Single Ocular Oncology Centre. Eye 37, 938–946 (2023). https://doi.org/10.1038/s41433-022-02051-0